19-33301691-C-T
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_004364.5(CEBPA):c.724G>A(p.Gly242Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000826 in 1,166,366 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_004364.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CEBPA | NM_004364.5 | c.724G>A | p.Gly242Ser | missense_variant | 1/1 | ENST00000498907.3 | NP_004355.2 | |
CEBPA | NM_001287424.2 | c.829G>A | p.Gly277Ser | missense_variant | 1/1 | NP_001274353.1 | ||
CEBPA | NM_001287435.2 | c.682G>A | p.Gly228Ser | missense_variant | 1/1 | NP_001274364.1 | ||
CEBPA | NM_001285829.2 | c.367G>A | p.Gly123Ser | missense_variant | 1/1 | NP_001272758.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CEBPA | ENST00000498907.3 | c.724G>A | p.Gly242Ser | missense_variant | 1/1 | NM_004364.5 | ENSP00000427514 | P1 | ||
ENST00000587312.1 | n.356+57C>T | intron_variant, non_coding_transcript_variant | 3 |
Frequencies
GnomAD3 genomes AF: 0.000323 AC: 48AN: 148506Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000326 AC: 1AN: 3068Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 1708
GnomAD4 exome AF: 0.000899 AC: 915AN: 1017752Hom.: 0 Cov.: 30 AF XY: 0.000881 AC XY: 425AN XY: 482458
GnomAD4 genome AF: 0.000323 AC: 48AN: 148614Hom.: 0 Cov.: 32 AF XY: 0.000276 AC XY: 20AN XY: 72484
ClinVar
Submissions by phenotype
Acute myeloid leukemia Uncertain:4Other:1
Uncertain significance, criteria provided, single submitter | clinical testing | St. Jude Molecular Pathology, St. Jude Children's Research Hospital | Feb 21, 2023 | The CEBPA c.724G>A (p.Gly242Ser) missense change has a maximum subpopulation frequency of 0.031% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL predicts a benign effect on protein function, but to our knowledge this prediction has not been confirmed by functional studies. This variant has been reported in an individual diagnosed with chronic lymphocytic leukemia with a family history of hematological malignancies and solid tumors (PMID: 19731081). To our knowledge, this variant has not been reported in individuals with familial acute myeloid leukemia. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 15, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
not provided, no classification provided | phenotyping only | GenomeConnect - Invitae Patient Insights Network | - | Variant classified as Uncertain significance and reported on 06-10-2016 by Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 17, 2023 | This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 242 of the CEBPA protein (p.Gly242Ser). This variant is present in population databases (rs530569305, gnomAD 0.03%). This missense change has been observed in individual(s) with familial hematological malignancies with solid tumors (PMID: 19731081). ClinVar contains an entry for this variant (Variation ID: 239927). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | May 20, 2022 | In silico analysis supports that this missense variant does not alter protein structure/function; Observed in an individual with chronic lymphocytic leukemia (El Abed 2009); This variant is associated with the following publications: (PMID: 19731081) - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Feb 01, 2024 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Jun 19, 2019 | - - |
Autosomal dominant familial acute myeloid leukemia Other:1
not provided, no classification provided | phenotyping only | GenomeConnect, ClinGen | - | GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at